Company intelligence / Profile preview

Lumara Bio Oncologics

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Lumara Bio is an early-stage biotechnology company dedicated to advancing the next generation of precision oncology treatments. The company focuses on developing targeted therapies for solid tumors, specifically addressing oncogenic drivers that have historically been considered undruggable. By leveraging a proprietary discovery platform, Lumara Bio aims to identify and exploit unique vulnerabilities within the tumor microenvironment and cancer cell signaling pathways. The firm is currently progressing its lead programs through pre-clinical development to establish a robust pipeline of high-impact cancer therapeutics.

Therapeutic areas: Oncology
Modalities: Small moleculeBiologicAntibody
Industry: Biotech

Beyond the preview

Go deeper on Lumara Bio Oncologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lumara Bio Oncologics.

Explore the full profile